3-Methyl-PCPy, also referred to as 3-Me-PCPy, is a derivative of arylcyclohexylamine known for its unique range of pharmacological effects.

IUPAC name
CAS Number1622348-63-3 
PubChem CID137332188
Chemical and physical data
Molar mass243.394 g·mol−1

Legal Status

3-Methyl-PCPy falls under drug analog regulations in several jurisdictions, including the UK, Germany, Japan, Australia, and others. It is categorized as a typical arylcyclohexylamine derivative and is considered a structural isomer of phencyclidine. These regulations apply to control and monitor its distribution and use.


1. What is 3-Methyl-PCPy?

  • 3-Methyl-PCPy, also known as 3-Me-PCPy, is a chemical compound belonging to the arylcyclohexylamine class, known for its unique pharmacological effects.

2. What are the pharmacological effects of 3-methyl-PCPy?

  • 3-Methyl-PCPy is recognized for its dual action as a potent NMDA antagonist and a triple reuptake inhibitor. This means it inhibits the reuptake of serotonin, dopamine, and noradrenaline and also interacts with sigma receptors.

3. What are the potential effects of using 3-Methyl-PCPy?

  • The effects of 3-Methyl-PCPy can vary but often include a combination of stimulant and dissociative effects, as observed in animal behavioral studies.

4. Is 3-methyl-PCPy legal?

  • The legal status of 3-Methyl-PCPy varies by country and jurisdiction. It is essential to be aware of the specific laws and regulations in your region regarding the possession and use of this substance.

5. What are the risks associated with 3-methyl-PCPy use?

  • Like many designer drugs, 3-methyl-PCPy carries potential health risks and adverse effects. These risks can include unpredictable reactions, overdose, and long-term consequences.

6. Can 3-methyl-PCPy be addictive?

  • While there may be a potential for psychological dependence with repeated use, it is not considered to be highly physically addictive like some other substances.

7. How can I reduce the risks associated with 3-methyl-PCPy use?

  • If you choose to use 3-Methyl-PCPy, it is advisable to start with a low dose, be in a safe environment, and have someone you trust present. Avoid combining it with other substances, and be aware of its potential side effects.

8. Is there a safe or recommended dosage for 3-methyl-PCPy?

  • The appropriate dosage can vary based on individual tolerance and experience. Beginning with a small amount and monitoring your body’s response is advisable.

9. Where can I find help or support for 3-Methyl-PCPy-related issues?

  • If you or someone you know is facing challenges related to 3-methyl-PCPy use or addiction, it is essential to seek professional help. Reach out to addiction treatment centers, healthcare providers, or support groups for guidance and assistance.

Please remember that this information is provided for educational purposes only. The use of designer drugs like 3-Methyl-PCPy can carry risks and legal implications. Always prioritize your health and safety and be aware of the laws in your area.


  1. Wallach J, De Paoli G, Adejare A, and Brandt SD conducted research in 2014 titled “Preparation and analytical characterization of 1-(1-phenylcyclohexyl)piperidine (PCP) and 1-(1-phenylcyclohexyl)pyrrolidine (PCPy) analogues.” This study was published in Drug Testing and Analysis, Volume 6 (7–8), and is accessible through DOI: 10.1002/dta.1468. The PMID for this study is 23554350.
  2. Morris H and Wallach J provided a comprehensive review of the non-medical use of dissociative drugs in their 2014 research, titled “From PCP to MXE.” This study was published in Drug Testing and Analysis, Volume 6 (7–8). You can access this review via DOI: 10.1002/dta.1620. The PMID for this review is 24678061.
  3. In 2018, Wallach J and Brandt SD contributed to the study “Phencyclidine-Based New Psychoactive Substances,” featured in the Handbook of Experimental Pharmacology, Volume 252. The study is accessible through DOI: 10.1007/164_2018_124. The ISBN for this volume is 978-3-030-10560-0, and the PMID for this research is 30105474.

Leave a Comment

Your email address will not be published. Required fields are marked *